First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Sources of information and study methodology
Open this folder and view contents3. Dissemination and uptake of the Guidelines
Open this folder and view contents4. Basic characteristics of drug donations
Open this folder and view contents5. Practical benefits as a result of the Guidelines
View the document6. Drug donations which were hampered, delayed or cancelled
Open this folder and view contents7. Experiences and opinions regarding the 12-month shelf-life requirement
Open this folder and view contents8. Other suggestions to improve the Guidelines
Close this folder9. How could donation practice be further improved?
View the documentDiscussing the Guidelines improves donation practice
View the documentGive more practical advice on good donation practice
View the documentRecommendations
View the document10. Summary of recommendations
View the document11. Postscript
View the documentReferences
 

Discussing the Guidelines improves donation practice

The Guidelines were never intended to serve as an international regulation; and they would never be accepted as such. However, they have certainly raised awareness of the potential benefits and problems of drug donations, and have often served as a starting point for intensive discussions within donor groups and between donor and recipient organizations. It was particularly these discussions, and a better exchange of information between donor and recipient, that have helped to rectify the imbalance between the two sides. Several recipients have confirmed that the Guidelines have enabled them to express openly how they would like to be helped, and have made it possible for them to refuse certain types of donations.

Thus it is the awareness and the discussion that have actually led to better donation practice, not the Guidelines themselves. This implies that further dissemination of the Guidelines is useful, and that governments and organizations should continue to be encouraged to discuss the issue of drug donations, and to develop their own guidelines.

to previous section to next section
 

Last updated: May 3, 2013